A Randomized Phase III, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients with Advanced Hepatocellular Carcinoma after failure of Sorafenib Treatment-The EVOLVE 1 Study
|Effective start/end date||7/24/10 → 3/1/13|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.